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Abstract 32 
Insomnia is one of the most common sleep problems with an estimated prevalence of 33 
10% to 15% in the general population. Although adenosine A2A receptor (A2AR) 34 
agonists strongly induce sleep, their cardiovascular effects preclude their use in treating 35 
sleep disorders. Enhancing endogenous A2AR signaling, however, may be an alternative 36 
strategy for treating insomnia, because adenosine levels in the brain accumulate during 37 
wakefulness. In the present study, we found that 3,4-difluoro-2-((2-fluoro-4-38 
iodophenyl)amino)benzoic acid, denoted A2AR positive allosteric modulator (PAM)-1, 39 
enhanced adenosine signaling at the A2AR and induced slow wave sleep (SWS) without 40 
affecting body temperature in wild-type male mice after intraperitoneal administration, 41 
whereas the SWS-inducing effect of this benzoic acid derivative was abolished in A2AR 42 
KO mice. In contrast to the A2AR agonist CGS 21680, the A2AR PAM-1 did not affect 43 
blood pressure or heart rate. These findings indicate that enhancing A2AR signaling 44 
promotes SWS without cardiovascular effects. Therefore, small molecules that 45 
allosterically modulate A2ARs could help people with insomnia to fall asleep.  46 
 47 
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1. Introduction  56 
Insomnia is one of the most common sleep problems with an estimated prevalence of 57 
10% to 15% in the general population and 30% to 60% in the older population (Roth, 58 
2007). Moreover, insomnia frequently co-occurs with a wide range of psychiatric 59 
disorders, including depression and anorexia (de Zambotti et al., 2017; Seow et al., 60 
2018). The most widely prescribed agents for the treatment of insomnia are 61 
benzodiazepines and non-benzodiazepines, which are central nervous system 62 
depressants that enhance signaling of the inhibitory neurotransmitter γ-aminobutyric 63 
acid (Wafford and Ebert, 2008). These medications, however, are plagued by a wide 64 
range of adverse effects, including muscle relaxation, rebound insomnia, changes in 65 
appetite, next-day sedation, cognitive impairment, amnesic effects, and development of 66 
drug tolerance and dependence (Aragona, 2000; Vgontzas et al., 1995). Orexin receptor 67 
antagonists were also recently developed and approved for treating insomnia (Cox et 68 
al., 2010). The major issues of these drugs are next-morning sleepiness with possible 69 
muscle weakness, strange dreams, sleep-walking, and other nighttime behaviors or 70 
suicidal ideation (Jacobson et al., 2014). Moreover, because orexin receptor antagonists 71 
mostly work by preventing arousal from sleep, they are generally ineffectual in people 72 
who have problems falling asleep. A highly selective adenosine A2A receptor (A2AR) 73 
agonist, CGS 21680, produces profound increases in sleep after infusion into the 74 
subarachnoid space underlying the ventral surface region of the rostral basal forebrain 75 
in rats, the lateral ventricle of mice, or the lateral preoptic area of rats (Satoh et al., 76 
1999; Scammell et al., 2001; Urade et al., 2003; Methippara et al., 2005). 77 
Administration of an A2AR agonist is not considered to have clinical potential for the 78 
treatment of sleep disorders, however, due to its adverse cardiovascular effects, which 79 
include hypotension and tachycardia (de Lera Ruiz et al., 2014). A positive allosteric 80 
modulator (PAM) may evoke selective physiologic A2AR responses because, in contrast 81 
to an A2AR agonist, its actions are limited to when and where adenosine is released. 82 
Adenosine levels in the brain progressively increase during wakefulness (Porkka-83 
Heiskanen et al., 1997), and therefore allosteric modulation of A2ARs to promote the 84 
somnogenic effects of the increased adenosine may be an alternative strategy for 85 
treating insomnia.  86 
In the present study, we identified a small lipophilic monocarboxylate (3,4-difluoro-2-87 
((2-fluoro-4-iodophenyl)amino)benzoic acid), denoted A2AR PAM-1, that induces 88 
slow-wave sleep (SWS), the major part of sleep characterized by slow and high-voltage 89 
brain waves, by enhancing A2AR signaling without affecting body temperature, blood 90 
pressure, or heart function in mice. 91 
 92 
2. Material and methods  93 
2.1. Reagents  94 
Adenosine (Nacalai Tesque, Kyoto, Japan), CGS 21680 (Sigma-Aldrich, St. Louis, 95 
MO), Cremophor® EL (Sigma-Aldrich), DMSO (Nacalai Tesque), DMEM (Nacalai 96 
Tesque), FBS (Nichirei Biosciences, Tokyo, Japan), HBSS (Gibco, Waltham, MA), 97 
hygromycin B (Wako, Tokyo, Japan), ketamine hydrochloride (Ketalar, Daiichi 98 
Sankyo, Tokyo, Japan), nonessential amino acids (NEAA; Nacalai Tesque), 99 
penicillin/streptomycin (Wako), pentobarbital (Somnopentyl, Kyoritsu Seiyaku, Tokyo, 100 
Japan), puromycin (InvivoGen, San Diego, CA), saline (Otsuka, Tokyo, Japan), 101 
Ultrance cAMP-kit (PerkinElmer, Waltham, MA), xylazine hydrochloride (Celactal, 102 
Bayer, Tokyo, Japan), ZM241385 (Tocris Bioscience, Bristol, UK), 3-isobutyl-1-103 
methylxanthine (IBMX; Tocris Bioscience) and HEPES (Gibco). 104 
 105 
2.2. Animals 106 
Male mouse lines on a C57BL/6 background, including wild-type and A2AR KO (Chen 107 
et al., 1999) mice, which were maintained at the International Institute of Integrative 108 
Sleep Medicine and weighing 21-27 g (10-15 weeks old), were used in the experiments. 109 
The animals were housed in an insulated and soundproof recording chamber that was 110 
maintained at an ambient temperature of 23 ± 0.5°C with a relative humidity of 50 ± 111 
5% and an automatically controlled 12 h light/12 h dark cycle (light on at 8:00, 112 
illumination intensity ≈ 100 lux). All animals had free access to food and water. This 113 
study was performed in strict accordance with the recommendations in the Guide for 114 
the Care and Use of Laboratory Animals of the US National Institutes of Health (2011). 115 
Experimental protocols were in compliance with relevant Japanese and institutional 116 
laws and guidelines and approved by the University of Tsukuba animal ethics 117 
committee (protocol #14-322). Every effort was made to minimize the number of 118 
animals used as well as any pain and discomfort experienced by the animals. 119 
 120 
2.3. Mouse A2AR-expressing Chinese hamster ovary cells 121 
The flag epitope-tagged open reading frame of A2AR was amplified by PCR from 122 
mouse brain total RNA.  The resultant amplicon was cloned into a pMXs-IRES-Puro 123 
retroviral vector (Kitamura et al., 2003). The plasmid was then transfected into the 124 
retrovirus packaging cell line Plat-E (Morita et al., 2000). The supernatant of 125 
transfected Plat-E cells was recovered after 24 h and applied to Chinese hamster ovary 126 
(CHO) cells strongly expressing the ecotropic receptor for the retrovirus (Montminy et 127 
al., 1990). Mouse A2AR-expressing CHO (mA2AR-CHO) cells were selected in DMEM 128 
supplemented with 5% FBS and 1% NEAA by treatment with hygromycin B (250 129 
μg·ml-1) and puromycin (10 μg·ml-1). The mA2AR-CHO cells were subsequently 130 
maintained in DMEM supplemented with 5% FBS, 1% NEAA, 1% 131 
penicillin/streptomycin, and 250 µg·ml-1 hygromycin B at 37°C in an atmosphere of 132 
5% CO2. 133 
 134 
2.4. cAMP assay 135 
Activation of A2ARs was quantified by cyclic adenosine monophosphate (cAMP) 136 
accumulation in CHO cells expressing mouse A2ARs. CHO cells were suspended in 137 
HBSS containing 1 M HEPES and 0.25 M IBMX in 384-well micro-plates (2×103 138 
cells/well), and incubated with adenosine and A2AR PAM-1 at the indicated 139 
concentrations for 30 min at 25°C. The detection mixture containing the Eu-cAMP 140 
tracer and ULight-anti-cAMP antibody was added and incubated for 1 h at 25°C. A 141 
micro-plate reader (ARVO X5, Perkin Elmer; excitation: 340 nm; emission: 665 nm) 142 
was used to measure the Förster resonance energy transfer (FRET) signal. All 143 
experiments were performed according to the manufacturer’s instructions (LANCE 144 
Ultra cAMP Kit, PerkinElmer). The cAMP levels are based on the dynamic range 145 
(“linear portion”) of the cAMP standard curve and normalized to the baseline or 146 
adenosine treated group. 147 
 148 
2.5. Stereotaxic surgery for the placement of EEG/EMG electrodes 149 
Mice were anesthetized with pentobarbital [50 mg·kg-1, intraperitoneal (i.p.)] and then 150 
placed in a stereotaxic apparatus. Electroencephalogram (EEG) and electromyogram 151 
(EMG) electrodes for polysomnographic recordings were chronically implanted in the 152 
mice (Oishi et al., 2016). The implant comprised two stainless steel screws (1 mm in 153 
diameter) inserted through the skull above the cortex (anteroposterior, +1.0 mm; left-154 
right, -1.5 mm from bregma or lambda) according to the atlas of Paxinos and Franklin 155 
(Paxinos and Franklin, 2004) that served as the EEG electrodes. Two insulated, 156 
stainless steel Teflon-coated wires were placed bilaterally into both trapezius muscles 157 
and served as the EMG electrodes. All electrodes were attached to a micro connector 158 
and fixed to the skull with dental cement.  159 
 160 
2.6. Pharmacologic treatment and infusion cannula implantation 161 
For control data, mice were injected with saline or vehicle (10 ml·kg-1 body weight, 162 
i.p.) at 22:00 or 21:30, respectively. A2AR PAM-1 was dissolved in saline immediately 163 
before use and administered intraperitoneally at 22:00 on the experimental day at a dose 164 
of 30, 60, or 75 mg·kg-1. ZM241385 (15 mg·kg-1, i.p.) was dissolved in vehicle (5% 165 
DMSO, 5% Cremophor® EL in saline) and injected into C57BL/6J mice at 21:30. Mice 166 
were randomly assigned to groups that received control or drug injections.  167 
For intracerebroventricular (i.c.v.) infusion of A2AR PAM-1, a stainless-steel cannula 168 
was inserted into mice during surgery 0.5 mm anterior and 1.6 mm lateral to bregma to 169 
a depth of 1.6 mm below the dura at an angle of 20°, thus placing the cannula into the 170 
lateral ventricle. To ensure correct placement of cannula, a plastic tube filled with saline 171 
was attached to the infusion cannula; a drop in the meniscus indicated that the cannula 172 
tip was in the ventricle. During the experiments, the mice were infused continuously 173 
using an infusion pump with artificial cerebrospinal fluid into the lateral ventricle of 174 
the brain at a speed of 1 µl·h-1. Sleep-wakefulness states were monitored for a period 175 
of 36 h after infusion of each compound. Saline infusion recordings were obtained in 176 
each animal for 36 h, beginning at 20:00, which served as the control for the same 177 
animal. In the next experiment, A2AR PAM-1 (200 nmol·h-1) was infused into the lateral 178 
ventricle of the mouse brain for 12 h (20:00 to 8:00). 179 
 180 
2.7. Vigilance state assessment based on EEG/EMG polygraphic recordings 181 
Ten days after surgery, the mice were individually housed in transparent barrels in an 182 
insulated soundproof recording chamber and connected to the EEG-EMG recording 183 
cables for 3 to 5 days of habituation before starting the polygraphic recordings. To 184 
evaluate the spontaneous sleep-wake cycle, each animal was recorded for 24 h 185 
beginning at 20:00, the onset of the dark period. The animals then entered the 186 
pharmacologic phase of the study in which sleep-wakefulness parameters were 187 
recorded for 36 h. The data collected during the first 24 h also served as baseline 188 
comparison data for the second experimental day. Cortical EEG/EMG recordings were 189 
amplified, filtered (EEG 0.5-30 Hz; EMG 20-200 Hz), and digitized at a sampling rate 190 
of 128 Hz, and then recording using data acquisition software SleepSign® (Kissei 191 
Comtec, Matsumoto, Japan). The vigilance states were classified offline in 10-s epochs 192 
into three stages, i.e., wakefulness, rapid eye movement (REM) sleep, and SWS by 193 
SleepSign® (ver 3.4) according to standard criteria (Oishi et al., 2016). As a final step, 194 
defined vigilance stages were examined visually, and corrected when necessary.  195 
 196 
2.8. Blood pressure and heart rate measurement 197 
The blood pressure of the mice was measured using the tail-cuff method with a BP-198 
98A blood pressure device (Softron, Tokyo, Japan).  The same time period (13:00 – 199 
16:00) was selected for testing the blood pressure of each mouse (9-12 weeks old) to 200 
avoid normal daily variations in blood pressure. Five consecutive days were used to 201 
habituate the mice to the device. To optimize cardiovascular circulation, mice were 202 
wrapped in a cotton sheet and, except for the tail, maintained at 37°C within a cylinder 203 
heater. A programmable sensor with an inflatable balloon attached to a tail cuff was 204 
used to monitor tail pulse waves and measure blood pressure when the pulse waves 205 
were stable and rhythmic. Blood pressure measurement was read and recorded by the 206 
software. After five consecutive training days, mice were randomly assigned to one of 207 
three groups and injected with saline (10 ml·kg-1, i.p.), A2AR PAM-1 (75 mg·kg-1, i.p.) 208 
or CGS 21680 (1 mg·kg-1, i.p.). Blood pressure was measured at 30 min, 1 h 30 min, 209 
and 2 h 30 min after injection (at each time-point, 20 readings for each mouse were 210 
collected). After testing, the mice were gently picked up by the tail and gently returned 211 
to their cages.  212 
The heart rate of the mice was measured by telemetry. Mice were anesthetized with 213 
ketamine hydrochloride (80 mg·kg-1, i.p.) and xylazine hydrochloride (8 mg·kg-1, i.p.) 214 
and a PhysioTel F20-ETA mouse telemetry transmitter (Data Science International, St. 215 
Paul, MN) was placed in the midline of the mouse back and fixed with surgical sutures. 216 
The negative (white) electrode was placed in the trapezius muscle, while the positive 217 
(red) electrode was sutured to a muscle in the back opposite the xiphoid process. Each 218 
mouse was singly housed in a cage after surgery with a distance of at least 1 m between 219 
cages to avoid interference between telemetry transmitters. After 7 days of recovery, 220 
the mice were randomly assigned to one of three groups and injected with saline (10 221 
ml·kg-1, i.p.), A2AR PAM-1 (75 mg·kg-1, i.p.), or CGS 21680 (1 mg·kg-1, i.p.). The 222 
transmitted cardiovascular signal was analyzed for 2 h after the injections using Data 223 
Science International software.  224 
 225 
2.9. Heart rhythm measurement  226 
The cardiac rhythm of mice was measured by electrocardiography (ECG). Mice were 227 
anesthetized with ketamine hydrochloride (80 mg·kg-1, i.p.) and xylazine hydrochloride 228 
(8 mg·kg-1, i.p.) and fixed with needles on a styrofoam platform. Mice were then gently 229 
pushed into a position where the two front paws and the left rear paw are in contact 230 
with 25-gauge needles that served as ECG electrodes. For intracardiac electrography, 231 
the throat of the mice was opened and the internal jugular vein was isolated to insert a 232 
catheter along the course of the vein to the right atrium. Electrographic signals were 233 
5.000-10.000-fold amplified and filtered (0.5-250 Hz) with an AC-601G system (Nihon 234 
Kohden, Tokyo, Japan). The same time period (10:00 – 12:00) was selected for testing 235 
the heart rhythm to avoid normal daily variations in the cardiac rhythm. Mice were 236 
randomly assigned to groups that received A2AR PAM-1 (75 mg·kg-1, i.p.) or CGS 237 
21680 (1 mg·kg-1, i.p.) injections. After recording the baseline for 1-2 minutes, mice 238 
were injected with drugs and recording continued for 30 minutes. The data were 239 
analyzed using LabChart Pro software (ADInstruments, Dunedin, New Zealand). 240 
 241 
2.10. Body temperature measurement  242 
The core body temperature of the mice was measured using Thermochron iButtons (KN 243 
Laboratories, Osaka, Japan). iButtons were programmed to monitor core body 244 
temperature every 5 min for 14 consecutive days beginning at the end of the recovery 245 
period. The mice were anesthetized with pentobarbital (50 mg·kg-1, i.p.). The skin of 246 
the abdomen was shaved and cleaned with 70% ethanol and a longitudinal, 2-cm 247 
incision was made along the midline. One iButton cleaned with 70% ethanol was placed 248 
in the peritoneal cavity and the incision was closed with nylon sutures. The mice were 249 
housed individually in cages after surgery and experiments were conducted after a 10-250 
day recovery period. iButtons were removed from the animals after cervical dislocation 251 
under anesthesia and RhManager software (KN Laboratories, Osaka, Japan) was used 252 
to collect the recorded data from the iButtons. 253 
 254 
2.11. Synthesis of A2AR PAM-1  255 
A solution of 2,3,4-fluorobenzoic acid (1.35 g, 7.68 mmol), 2-fluoro-4-iodoaniline 256 
(1.91 g, 8.06 mmol), and lithium amide (0.702 g, 30.6 mmol) in tetrahydrofuran (10.5 257 
mL) was reacted using a standard method (Cai et al., 2008) to give 3,4-difluoro-2-((2-258 
fluoro-4-iodophenyl)amino)benzoic acid (A2AR PAM-1, 2.99 g, 99%) as a brown solid 259 
(Figure S1); IR (KBr) 3311, 1673, 1602, 1520, 1500, 1444, 1273, 768 cm-1; 1H NMR 260 
(400 MHz CD3OD) δ = 7.89 (1 H, ddd, J = 2.3, 6.0, 9.2 Hz), 7.48 (1 H, dd, J = 1.8, 261 
10.5 Hz), 7.41 (1 H, ddd, J =1.4, 1.8, 8.5 Hz), 6.91 (1 H, ddd, J = 7.3, 9.4, 9.4 Hz), 6.75 262 
(1 H, ddd, J = 5.6, 8.5, 8.5 Hz); 13C NMR (100 MHz acetone-d6) δ = 169.9, 155.7 (dd, 263 
JC,F = 252.1, 4.8 Hz), 155.6 (d, JC,F = 252.1 Hz), 143.6 (dd, JC,F = 247.8, 14.9 Hz), 137.4 264 
(dd, JC,F = 7.7, 2.9 Hz), 135.0 (d, JC,F = 3.8 Hz), 131.9(d, JC,F = 11.5 Hz), 129.8 (dd, JC,F 265 
= 9.6, 3.8 Hz), 125.8 (d, JC,F = 21.0 Hz), 123.8 (d, JC,F = 5.8 Hz), 116.4, 110.1 (d, JC,F 266 
= 18.2 Hz), 84.7 (d, JC,F = 6.7 Hz); HRMS-ESI: m/z [M-H]- calcd for C13H6F3INO2, 267 
391.9395; measured, 391.9414. 268 
 269 
2.12. Formation of the sodium salt of A2AR PAM-1 270 
Aqueous sodium hydroxide (100 μM, 754 μL) was added to a stirred solution of A2AR 271 
PAM-1 (0.266 g, 75.4 mmol) in ethanol (20.0 mL) at 0°C. The mixture was stirred for 272 
45 min at room temperature and then concentrated in vacuo and freeze-dried. The 273 
residue was dissolved in water and filtered. The filtrate was freeze-dried to obtain the 274 
sodium salt of A2AR PAM-1 (0.265 g, 89%) as a gray solid (m.p. 290−291°C; Anal. 275 
Calcd for C13H6NO2·Na·1.5H2O: C, 35.32; H, 2.05; N, 3.17. Measured: C, 35.34; H, 276 
1.91; N, 3.14). The sodium salt of A2AR PAM-1 was used for all in-vivo experiments.  277 
 278 
2.13. Statistical analysis 279 
Statistical analyses were carried out using Systat Software (SigmaPlot). All results are 280 
presented as mean ± standard error of the mean (SEM). Two-tailed Student’s t-tests 281 
were used for statistical comparisons between two groups (Fig. 1A, B, D, E, Fig. 2C, 282 
D, F, Fig. 3B, D, Fig. 4B, Fig. 5A, B, Fig. S2A, B, Fig. S4B, Fig. S5A-C, and Fig. S6A-283 
C). For t-tests, the normality of each dataset was established using the Kolmogorov–284 
Smirnov test. Two-way repeated-measures analysis of variance (ANOVA) followed by 285 
the Tukey test were used for dose-response effects on the amounts of the SWS, REM 286 
sleep, and wakefulness (Fig. 2B, Fig. 3A, C, Fig. 4A, Fig. S3A and Fig. S5A) (Chrivia 287 
et al., 1993).  In all of the cases, P <0.05 was considered significant (significance levels 288 
are indicated in figures as *: P<0.05, **: P <0.01 or ***: P <0.001).  289 
 290 
3. Results 291 
3.1. Screening of small-molecule compounds for allosteric A2AR modulation 292 
We established CHO cells that express mouse A2ARs (Figure S2) using a retrovirus-293 
mediated gene transfer method (Kitamura et al., 2003). We used these mA2AR-CHO 294 
cells to screen 1173 small-molecule compounds for their allosteric effects at A2ARs. 295 
The compounds were synthesized in Dr. Hiroshi Nagase’s laboratory at the University 296 
of Tsukuba. A2AR activity in CHO cells was determined by measuring cAMP produced 297 
after adding adenosine and small-molecule compounds using a fluorescence resonance 298 
energy transfer immunoassay. Because a one-compound-one-well approach may be 299 
wasteful research conduct due to a likely small number of active compounds in our 300 
library, we tested initially 391 mixtures containing three compounds each in triplicates. 301 
We selected mixtures that significantly enhanced the effects of adenosine at the A2ARs 302 
(P<0.01, unpaired t-test) for individual compound testing and found that eight of the 303 
mixtures showed an effect according to this criterion (Mixture 124: t(4)=27.9, P<0.0001, 304 
Mixture 181: t(4)=31.5, P<0.0001, Mixture 194: t(4)=30.9, P<0.0001, Mixture 211: 305 
t(4)=9.6, P=0.0006, Mixture 274: t(4)=11, P=0.0003, Mixture 319: t(4)=6.81, P=0.0024, 306 
Mixture 332: t(4)=8.62, P=0.0009, Mixture 346: t(4)=4.71 P=0.0091, unpaired t-test; 307 
Figure 1A). Further individual testing of compounds in the eight mixtures revealed that 308 
only compound 371 (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid) in 309 
mixture 124 enhanced adenosine-induced A2AR activation (t(4)=9.14, P=0.0007, 310 
unpaired t-test; Figure 1B). A cell culture bioassay revealed that cAMP levels were not 311 
altered by treating A2AR-expressing or native CHO cells with compound 371 in the 312 
absence of adenosine or by treating native CHO with adenosine and compound 371 313 
(Figure 1C), suggesting that compound 371 is likely a positive allosteric modulator for 314 
A2ARs, and we therefore named this compound A2AR PAM-1. Co-treatment of A2AR-315 
expressing CHO cells with 150 nM adenosine and various concentrations of A2AR 316 
PAM-1 (i.e., 25, 50, and 100 µM) amplified adenosine A2AR-evoked cAMP 317 
accumulation in a dose-dependent manner by 42% ± 1.4%, 46% ± 1.1%, and 50% ± 318 
1.0%, respectively (25 µM A2AR PAM-1: t(4)=4.47, P=0.011, 50 µM A2AR PAM-1: 319 
t(4)=7.21, P=0.0019, 50 µM A2AR PAM-1 vs. 25 µM A2AR PAM-1: t(4)=4.71, P=0.0092, 320 
100 µM A2AR PAM-1: t(4)=9 P=0.0008, 100 µM A2AR PAM-1 vs. 25 µM A2AR PAM-321 
1: t(4)=8.08, P=0.0012, 100 µM A2AR PAM-1 vs. 50 µM A2AR PAM-1: t(4)=3.65, 322 
P=0.021, unpaired t-test; Figure 1D).  Similarly, co-treatment of A2AR-expressing 323 
CHO cells with 100 µM A2AR PAM-1 and 50, 100, or 150 nM adenosine increased 324 
A2AR activity in the CHO cells in a dose-dependent manner by 55% ± 0.4%, 66% ± 325 
1.5%, and 72% ± 1.7%, whereas 100 µM A2AR PAM-1 did not significantly enhance 326 
the cellular activity of A2AR-expressing CHO cells treated with 250 nM adenosine (50 327 
nM Adenosine: t(4)=14.9, P=0.0001, 50 nM Adenosine vs. 100 nM Adenosine: t(4)=7.04, 328 
P=0.0021, 50 nM Adenosine vs. 150 nM Adenosine: t(3)=12.40, P=0.0011, 50 nM 329 
Adenosine vs. 250 nM Adenosine: t(4)=11.79, P=0.00029, 100 nM Adenosine: t(4)=6.18, 330 
P=0.034, 150 nM Adenosine: t(3)=4.98, P=0.015, unpaired t-test; Figure 1E).  331 
 332 
3.2. Intraperitoneal administration of A2AR PAM-1 induces SWS without affecting body 333 
temperature in mice 334 
We then tested the effect of intraperitoneal administration of A2AR PAM-1 on the 335 
sleep/wake behavior of wild-type mice. We analyzed EEG and EMG recordings made 336 
after saline or A2AR PAM-1 injections during the dark period at 22:00, when mice 337 
usually spend most of their time awake. Although baseline sleep and wake of mice 24 338 
h prior to treatment was not significantly different between the saline and A2AR PAM-339 
1 groups during the dark period (Figure S3), A2AR PAM-1 dose-dependently increased 340 
SWS after the injections for the following 8 h (SWS: F(1,106)=13.97, P=0.033, two way 341 
repeated measures ANOVA-Tukey test, 30 mg·kg-1 A2AR PAM-1 vs. 60 mg·kg-1 A2AR 342 
PAM-1: t(7)=4.36, P=0.0032, 30 mg·kg-1 A2AR PAM-1 vs. 75 mg·kg-1 A2AR PAM-1: 343 
t(6)=5.45, P=0.0015, unpaired t-test; Figure 2A, B, D). The total amount of SWS was 344 
increased by 60.8 ± 11.4 min for 8 h with the highest dose of A2AR PAM-1 (i.e., 75 345 
mg·kg-1) compared with saline treatment, whereas wakefulness was decreased by 59.2 346 
± 12.8 min (SWS: t(7)=4.27, P=0.0036, Wake: t(7)=4.33, P=0.0034, unpaired t-test; 347 
Figure 2C). Intraperitoneal injection of A2AR PAM-1 did not significantly alter the 348 
REM sleep duration during the dark period compared with saline injection.  349 
Administration of A2AR PAM-1 (75 mg·kg-1, i.p.) to the mice did not significantly 350 
affect the episode numbers of SWS and REM sleep for 8 h in the dark period (Figure 351 
S4A). On the other hand, wake episode numbers lasting 120 to 239 s increased by 307% 352 
(t(7)=3.88, P=0.006, unpaired t-test), and wake episode numbers lasting 480 to 959 s 353 
and 960 to 1909 s decreased by 47% (t(7)=2.89, P=0.02, unpaired t-test) and 88% 354 
(t(7)=4.60, P=0.002, unpaired t-test), respectively, compared with the saline injection. 355 
The mean duration of wake episodes decreased by 38% (t(7)=3.38, P=0.01, unpaired t-356 
test) compared with saline, but the duration of the SWS and REM sleep episodes was 357 
not significantly different after A2AR PAM-1 (75 mg·kg-1, i.p.) administration (Figure 358 
S4B). A2AR PAM-1 (75 mg·kg-1, i.p.) also did not significantly affect the number of 359 
transitions between SWS, wake, and REM sleep (Figure S4C). 360 
To assess whether EEG activity was altered by A2AR PAM-1 administration, we 361 
compared the normalized EEG power spectrum of SWS in mice treated with saline or 362 
A2AR PAM-1 (Figure 2E). EEG activity in the frequency range of 0.5–25 Hz during 363 
SWS was indistinguishable between A2AR PAM-1–induced and natural (saline 364 
injection) SWS. These data suggest that A2AR PAM-1 induced physiologic sleep rather 365 
than abnormal sleep.  366 
We also measured the effect of intraperitoneal administration of 75 mg·kg-1 A2AR 367 
PAM-1 or 1 mg·kg-1 of the A2AR agonist CGS 21680 (as positive control) on the body 368 
temperature of the mice during the dark period (Figure 2F). Although CGS 21680 369 
strongly decreased the body temperature for almost 2 h (t(10)=3.68, P=0.0042 at 22:15, 370 
t(10)=10.48, P<0.0001 at 23:15, t(10)=2.33, P=0.041 at 00:05 vs. saline injected group, 371 
unpaired t-test), A2AR PAM-1 did not affect the body temperature of the mice. These 372 
data suggest that A2AR PAM-1 induces physiologic sleep independent of the body 373 
temperature.  374 
 375 
3.3. Sleep-inducing effect of A2AR PAM-1 was suppressed by blocking A2ARs 376 
We further investigated whether A2ARs mediate the sleep-inducing effect of A2AR 377 
PAM-1. First, we pretreated wild-type mice with the selective A2AR antagonist 378 
ZM241385 (15 mg·kg-1, i.p.) or vehicle 30 min before the A2AR PAM-1 injection at 379 
22:00. The dose of ZM241385 was selected based on previous studies (El Yacoubi et 380 
al., 2000; Nakamura et al., 2016). In the presence of ZM241385, A2AR PAM-1 injection 381 
produced no significant changes in SWS (Figure 3A), indicating that ZM241385 382 
completely blocked the A2AR PAM-1–induced SWS. When we calculated the total 383 
amount of SWS for 4 h after the intraperitoneal injection of A2AR PAM-1 (Figure 3B), 384 
we found that it did not significantly alter the total amount of SWS after ZM241385 385 
pretreatment. ZM241385 pretreatment alone also had no significant effect on SWS 386 
compared with vehicle pretreatment (Vehicle + Saline vs. Vehicle + 75 mg·kg-1 A2AR 387 
PAM-1: t(8)=4.04, P=0.0037, 15 mg·kg-1 ZM241385 + 75 mg·kg-1 A2AR PAM-1 vs. 388 
Vehicle + 75 mg·kg-1 A2AR PAM-1: t(8)=2.63, P=0.029, 15 mg·kg-1 ZM241385 + 389 
Saline vs. Vehicle + 75 mg·kg-1 A2AR PAM-1: t(8)=6.10, P=0.00028, unpaired t-test; 390 
Figure 3B).  391 
We then administered 75 mg·kg-1 A2AR PAM-1 (i.p.) into A2AR KO mice and their 392 
wild-type littermates at 22:00. We observed no significant changes in SWS in the A2AR 393 
KO mice compared with saline treatment, whereas SWS was increased by 74.3 ± 12.0 394 
min for 6 h in wild-type littermates of A2AR KO mice (F(1,190)=20.83, P=0.003, two way 395 
repeated measures ANOVA-Tukey test, t(14)=5.63, P<0.0001, unpaired t-test; Figure 396 
3C, D). Concomitantly, wakefulness was decreased in the wild-type littermates of A2AR 397 
KO mice (F(1,190)=16.14, P=0.005, two way repeated measures ANOVA-Tukey test, 398 
t(14)=5.50, P<0.0001, unpaired t-test), whereas neither REM sleep in these mice nor 399 
wakefulness and REM sleep in the KO mice were affected by intraperitoneal 400 
administration of 75 mg·kg-1 A2AR PAM-1 (Figure S5). Baseline sleep and wake of 401 
the KO mice and their wild-type littermates 24 h prior to treatment was not different 402 
between the saline and A2AR PAM-1 groups during the dark period (data not shown). 403 
These findings suggest that A2AR are necessary for A2AR PAM-1 to induce SWS.  404 
 405 
3.4. Intracerebroventricular administration of A2AR PAM-1 induces SWS in mice 406 
To elucidate whether the sleep-inducing effect of A2AR PAM-1 is mediated via A2ARs 407 
expressed in the brain, we infused A2AR PAM-1 into the lateral ventricle of wild-type 408 
mice at 200 nmol·h-1 during the dark period (20:00 to 8:00) and assessed EEG and 409 
EMG activity. Infusion with A2AR PAM-1 for 12 h increased the time spent in SWS 5 410 
h after the infusion, resulting in a total SWS increase during the dark period of 141.6 ± 411 
12.5 min compared with saline infusion (F(1,118)=34.40, P=0.004, two way repeated 412 
measures ANOVA-Tukey test, t(8)=5.67, P=0.00047, unpaired t-test; Figure 4A, B). 413 
Concomitantly, total wakefulness was decreased by 145.5 ± 15.8 min during a 12-h 414 
i.c.v. infusion of A2AR PAM-1 (F(1,118)=43.46, P=0.003, two way repeated measures 415 
ANOVA-Tukey test, t(8)=5.08, P=0.00095, unpaired t-test), whereas REM sleep was 416 
not affected. 417 
Intracerebroventricular infusion of A2AR PAM-1 (200 nmol·h-1) into mice affected 418 
SWS and wake episode numbers during the dark period (Figure S6A).  SWS episode 419 
numbers lasting 0 to 29 s, 30 to 59 s, and 60 to 120 s increased by 267% (t(8)=7.56, 420 
P<0.0001, unpaired t-test), 196% (t(8)=3.47, P=0.008, unpaired t-test), and 154% 421 
(t(8)=2.88, P=0.02, unpaired t-test), respectively, and wake episode numbers lasting 0 422 
to 29 s, 30 to 59 s, and 60 to 120 s also increased by 205% (t(8)=3.97, P =0.004, unpaired 423 
t-test), 177% (t(8)=3.55, P=0.007, unpaired t-test), and 137% (t(8)=2.77, P=0.02, 424 
unpaired t-test), respectively, compared with saline infusion. On the other hand, episode 425 
numbers of REM sleep were not significantly affected by A2AR PAM-1 infusion (200 426 
nmol·h-1, i.c.v.). The mean duration of wake episodes decreased by 72% (t(8)=3.06, 427 
P=0.01, unpaired t-test) compared with the saline-infused group, but mean episode 428 
duration of the SWS and REM sleep did not significantly change after A2AR PAM-1 429 
(200 nmol·h-1, i.c.v.) administration (Figure S6B). A2AR PAM-1 (200 nmol·h-1, i.c.v.) 430 
increased the number of transitions between SWS and wakefulness by 148% (t(8)=4.91, 431 
P =0.001, unpaired t-test), and from wakefulness to SWS by 128% (t(8)=4.26, P=0.002, 432 
unpaired t-test) compared with the saline-infused group (Figure S6C).  433 
Moreover, the EEG activity in the frequency range of 0.5–25 Hz during SWS episodes 434 
was indistinguishable between mice treated with saline or A2AR PAM-1 (Figure 4C). 435 
These data suggest that A2AR PAM-1 induces physiologic sleep rather than abnormal 436 
sleep via A2ARs that are likely expressed in the brain. 437 
 438 
3.5. Intraperitoneal administration of A2AR PAM-1 does not affect blood pressure or 439 
heart rate 440 
A2AR agonists evoke cardiovascular effects (Hutchison et al., 1989; Kirkup et al., 1998; 441 
Nekooeian and Tabrizchi, 1996). We therefore tested the effect of intraperitoneal 442 
administration of A2AR PAM-1 on blood pressure and heart rate in wild-type mice. First, 443 
we measured blood pressure in mice 30, 90, and 150 min after intraperitoneal injection 444 
of 75 mg·kg-1 A2AR PAM-1 or 1 mg·kg-1 of the A2AR agonist CGS 21680 using an 445 
electrosphygmomanometer (Figure 5A). The dose of the A2AR agonist CGS 21680 was 446 
selected based on previous studies in mice (Carvalho et al., 2017; Nakav et al., 2008; 447 
Ohta and Sitkovsky, 2001). Compared with saline treatment, the systolic, and diastolic 448 
blood pressures were significantly decreased for up to 90 min after injecting the A2AR 449 
agonist CGS 21680 (SBP at 30 min: t(9)=10.55, P<0.0001, SBP at 90 min: t(9)=7.51, 450 
P<0.0001, DBP at 30 min: t(9)=6.60, P<0.0001, DBP at 90 min: t(9)=5.86, P<0.0001, 451 
unpaired t-test) and returned to normal levels within 150 min after the injection. In 452 
contrast, blood pressure was not changed after intraperitoneal administration of A2AR 453 
PAM-1 (75 mg·kg-1) at 30, 90, or 150 min after treatment. In addition, we measured 454 
the heart rate of mice after intraperitoneal injection of 75 mg·kg-1 A2AR PAM-1 or 1 455 
mg·kg-1 A2AR agonist CGS 21680 using the telemetry implants (Figure 5B). The heart 456 
rate of the mice increased after intraperitoneal administration of the A2AR agonist CGS 457 
21680 (HR at 60 min: t(8)=2.34, P=0.047, HR at 75 min: t(8)=2.90, P=0.019, HR at 90 458 
min: t(8)=2.80, P=0.023, unpaired t-test), whereas the heart rate was not affected by 459 
injection of 75 mg·kg-1 A2AR PAM-1. Finally, we monitored the heart rhythm in 460 
anesthetized mice after intraperitoneal administration of 75 mg·kg-1 of A2AR PAM-1 or 461 
1 mg·kg-1 of A2AR agonist CGS 21680 using intracardiac EGM. We observed sinus 462 
arrhythmia in mice after intraperitoneal administration of A2AR agonist CGS 21680, 463 
whereas injection of 75 mg·kg-1 A2AR PAM-1 did not cause abnormalities of the cardiac 464 
rhythm (Figure 5C). 465 
 466 
4. Discussion 467 
Our observations suggest that enhancing A2AR signaling by intraperitoneal 468 
administration of A2AR PAM-1 induces SWS without cardiovascular effects in mice. 469 
Therefore, A2AR-modulating compounds may provide safe options for the treatment of 470 
insomnia and poor-quality sleep.  471 
Over the past century, several putative hypnogenic substances implicated in the sleep 472 
homeostatic process have been identified, including prostaglandin D2 (Qu et al., 2006), 473 
cytokines (Krueger et al., 1984), anandamide (García-García et al., 2009), urotensin II 474 
peptide (Huitron-Resendiz et al., 2005), and adenosine (Porkka-Heiskanen et al., 1997). 475 
Adenosine represents a state of relative energy deficiency: ATP depletion positively 476 
correlates with an increase in extracellular adenosine levels (Kalinchuk et al., 2003) 477 
and positively associates with sleep (Porkka-Heiskanen et al., 1997). Adenosine levels 478 
in samples collected from several brain areas of cats during spontaneous sleep-wake 479 
cycles by in vivo microdialysis were higher during SWS than during wakefulness for 480 
all probed brain areas (Porkka-Heiskanen et al., 1997). The observation in animals that 481 
adenosine levels are elevated during prolonged wakefulness may explain why an 482 
allosteric modulator could effectively enhance the sleep-inducing effect of endogenous 483 
adenosine in the brain. On the other hand, adenosine is absent or its concentration is 484 
too low in the cardiovascular system under physiologic conditions to affect blood 485 
pressure and heart function after administration of an allosteric modulator of A2AR. 486 
Medicinal chemistry for A2ARs has been widely developed in recent decades for use in 487 
myocardial perfusion imaging and the treatment of inflammation and neuropathic pain 488 
(de Lera Ruiz et al., 2014). Several A2AR agonists that entered clinical trials elicited 489 
undesirable side effects, however, thus precluding their further development. On the 490 
other hand, allosteric modulators bind at a distinct site other than the natural ligand 491 
binding site (i.e., the orthosteric site) and exert their effects only in the presence of the 492 
orthosteric ligand (Wenthur et al., 2014). As a consequence, an allosteric modulator 493 
mimics the activity duration of the natural ligand and thus the pharmacologic response 494 
of an allosteric modulator more closely resembles the natural physiologic activity of 495 
the receptor than is possible with a synthetic agonist. Because efforts to evoke 496 
pharmacologic A2AR responses have focused almost exclusively on the use of 497 
orthosteric ligands, however, the possibility that A2AR responses, especially in the brain, 498 
can be fine-tuned using allosteric modulators has received very little attention (Göblyös 499 
and Ijzerman, 2009).  500 
Moreover, it is widely accepted that the basic adenosine scaffold must be maintained 501 
in an A2AR agonist (Fredholm et al., 2011). Thus, the development of adenosine analogs 502 
for treating the central nervous system, including sleep induction for treating insomnia, 503 
is restricted by the poor transport of these drugs through the brain endothelial cells, 504 
which are connected by tight junctions to establish a blood-brain barrier (BBB) 505 
(Pardridge et al., 1994). In contrast, A2AR PAM-1, when administered intraperitoneally, 506 
exhibits a sleep-inducing effect that is likely mediated by A2ARs in the brain and thus 507 
appears to cross the BBB. Small lipophilic monocarboxylates like A2AR PAM-1 likely 508 
pass through the BBB by passive diffusion or via a monocarboxylate transport system 509 
(Tsuji, 2005). Therefore, allosteric modulation of A2ARs has the potential to cause 510 
pharmacologic effects in the central nervous system after systemic administration, 511 
resulting in good quality sleep. 512 
Our study did not investigate how and where the A2AR PAM-1 binds at the receptor to 513 
exert its allosteric effect. Therefore, an important next step will be to examine the 514 
allosteric interactions of A2AR PAM-1 and the receptor using binding assays and crystal 515 
structure analysis. With respect to the latter, a crystal structure of the human A2AR 516 
bound to a bitopic antagonist revealed a potential allosteric pocket (Sun et al., 2017) 517 
and another study suggested that a sodium ion binding site can be exploited for 518 
allosteric modulation of A2AR (Gutiérrez-de-Terán et al., 2013). Moreover, to solidify 519 
the sleep enhancing effect of the A2AR PAM-1, it may be necessary to test the A2AR 520 
PAM-1 in mice at the time of normal sleep onset, i.e., A2AR PAM-1 administration at 521 
the onset of the light period, or in an animal model of insomnia, for example, a mouse 522 
model mimicking the human first-night effect (Xu et al., 2014).   523 
Due to work schedules and expectations, lifestyle choices, pre-existing medical 524 
conditions, or aging, people are coping with an increasingly wide range of sleep 525 
problems, including difficulties with falling and staying asleep, waking up too early, 526 
and poor-quality ("non-restorative") sleep. Deficiencies in sleep cause significant social 527 
losses due to increased prevalence of mood disorders, lead to decreased economic 528 
productivity, and are linked to traffic and work-related accidents due to excessive 529 
daytime sleepiness (Groeger et al., 2004; Saddichha, 2010; Sutton et al., 2001). 530 
Insufficient sleep is not only by itself a major problem in modern society, but is also an 531 
established risk factor for obesity, diabetes, heart disease, and other lifestyle diseases 532 
(Colten et al., 2006). Moreover, psychiatric illnesses, especially anxiety and mood 533 
disorders, are long recognized to be a frequent cause of insomnia (Okuji et al., 2002).  534 
 535 
5. Conclusions 536 
The findings of our study indicate that enhancing A2AR signaling promotes SWS 537 
without cardiovascular effects. Therefore, small molecules that allosterically modulate 538 
A2ARs could help people with sleep problems to fall asleep and thus also be a potential 539 
treatment for psychiatric disorders. 540 
Our study was conducted in mice, the most commonly used model organism of human 541 
disease. Results in mice, however, are not particularly reliable for predicting human 542 
study outcomes, mostly due to the limited genetic diversity associated with common 543 
laboratory mice. Therefore, many obstacles remain to be overcome in generating a 544 
novel drug for the treatment of insomnia in humans.  545 
 546 
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Figures and legends 736 
 737 
Fig. 1. Co-treatment of mA2AR-CHO cells with A2AR PAM-1 and adenosine revealed 738 
allosteric modulation. (A) High-throughput screening of small-molecule compounds. 739 
Changes of cAMP levels in CHO cells after treatment with adenosine and compound 740 
mixtures are shown as percentage of cAMP levels in CHO cells after treatment with 741 
adenosine. Screening experiments were performed in triplicate wells. (B) FRET 742 
activity in mA2AR-expressing CHO cells after treatment with adenosine and small 743 
molecule compounds 370, 371, or 372. (C) FRET activity in mA2AR-expressing (left 744 
panel) and native (right panel) CHO cells after treatment with adenosine or adenosine 745 
and A2AR PAM-1, respectively. (D, E) Dose-dependent changes of cAMP level in 746 
mA2AR-expressing CHO cells after treatment with adenosine and different 747 
concentrations of A2AR PAM-1 (D) or A2AR PAM-1 and different concentrations of 748 
adenosine (E). (B-E) Experiments were performed in triplicate wells for each condition 749 
and repeated at least twice. Representative data are shown. Data are presented as mean 750 
± SEM.  751 
 752 
Fig. 2. Intraperitoneal administration of A2AR PAM-1 induces SWS without affecting 753 
body temperature in mice. (A) Typical examples of EEG, EMG, and hypnograms of a 754 
mouse after the administration of saline (top panel) or A2AR PAM-1 (bottom panel). (B, 755 
C) Time-courses (B) and total amounts (C) of SWS, REM sleep, and wakefulness in 756 
mice after intraperitoneal administration of saline or A2AR PAM-1.  (D) Dose-757 
dependent changes in SWS time during 8 h after A2AR PAM-1 administration 758 
normalised to the SWS time of the vehicle control. (E) EEG power density of SWS for 759 
8 h after saline or A2AR PAM-1 administration. Data are presented as mean ± SEM 760 
(n=5/group). (F) Body temperature of mice after intraperitoneal administration of saline, 761 
A2AR PAM-1 or CGS 21680. Data are presented as mean ± SEM (n=6/group). 762 
 763 
 764 
Fig. 3. Sleep inducing effect of A2AR PAM-1 depends on adenosine A2AR in mice. (A, 765 
B) Time-courses (A) and total amount (B) of SWS in mice pretreated with vehicle or 766 
the A2AR antagonist ZM 241385 after administration of saline or A2AR PAM-1 767 
(n=5/group, respectively). (C, D) Time-courses (C) and total amount (D) of SWS in 768 
wild-type (top panels) or A2AR KO mice (bottom panels) after administration of saline 769 
or A2AR PAM-1 (8/group). Data are presented as mean ± SEM. 770 
 771 
 772 
Fig. 4. Intracerebroventricular infusion of A2AR PAM-1 induced SWS in mice. (A, B) 773 
Time-courses (A) and total amount of SWS, REM sleep, and wakefulness (B) in mice 774 
after intracerebroventricular infusion of saline or A2AR PAM-1. (C) EEG power density 775 
of SWS during the infusion of saline or A2AR PAM-1. Data are presented as mean ± 776 
SEM (n=5/group). 777 
 778 
Fig. 5. A2AR PAM-1 does not affect the cardiovascular system. (A) Systolic, and 779 
diastolic blood pressure after A2AR PAM-1 or CGS 21680 injection in mice 780 
(n=5/group). (B) Heart rate of mice after injection of saline, A2AR PAM-1, or CGS 781 
21680, assessed by the telemetry implants (n=5/group). (A, B) Data are presented as 782 
mean ± SEM. (C) Typical heart rhythm profiles of mice without treatment (left panel) 783 
or after administration of A2AR PAM-1 (middle panel) or CGS 21680 (right panel). Red 784 
and blue left/right arrows in the right panel indicate sinus arrhythmia. Abbreviations 785 
used: SBP, systolic blood pressure; DBP, diastolic blood pressure; ECG, 786 
electrocardiogram; IC-EGM, intracardiac electrogram; A, atrial signal; V, ventricular 787 
signal.  788 
Supplementary figures and legends 789 
 790 
Fig. S1. Chemical synthesis of A2AR PAM-1. A2AR PAM-1 (3) was produced by 791 
combining 2,3,4-fluorobenzoic acid (1) and 2-fluoro-4-iodoaniline (2). 792 
 793 
 794 
Fig. S2. Characterization of mouse A2AR-expressing CHO cells. (A) Cell number-795 
dependent FRET activity of mA2AR-expressing CHO. (B) Dose-dependent changes of 796 
FRET activity in mA2AR-expressing CHO after adenosine administration. (C) 797 
Expression of Chinese hamster adenosine receptors in mA2AR-expressing (left panel) 798 
and native (right panel) CHO cells.  799 
 800 
 801 
Fig.  S3. Baseline sleep/wake profile of the mice before treatment. (A, B) Time-802 
courses (A) and total amount of sleep (top panels; combined SWS and REM sleep 803 
amounts) and wakefulness (bottom panels) in mice over 24 h. Data are presented as 804 
mean ± SEM (n=5/group). 805 
 806 
 807 
Fig. S4. Sleep architecture of mice after intraperitoneal administration of A2AR PAM-808 
1. (A, B) Episode number (A) and mean duration (B) of each stage after administration 809 
of saline or A2AR PAM-1. (C) Transitions between SWS (S), REM sleep (R), and wake 810 
(W) stages after administration of saline or A2AR PAM-1. Data are presented as mean 811 
± SEM (n=5/group). 812 
 813 
 814 
Fig. S5. REM sleep and wakefulness in wild-type and A2AR KO mice after 815 
intraperitoneal administration of A2AR PAM-1. (A-D) Time-courses (A and C) and total 816 
amount (B and D) of REM sleep (top panels) and wakefulness (bottom panels) in wild-817 
type (A and B) and A2AR KO mice (C and D). Data are presented as mean ± SEM 818 
(n=8/group). 819 
 820 
 821 
Fig. S6. Sleep architecture of mice after intracerebroventricular infusion of A2AR PAM-822 
1. (A, B) Episode number (A) and mean duration (B) of each stage after infusion of 823 
saline or A2AR PAM-1. (C) Transitions between SWS (S), REM sleep (R), and wake 824 
(W) stages after infusion of saline or A2AR PAM-1. Data are presented as mean ± SEM 825 
(n=5/group). 826 
 827 
